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CORONARY ARTERY ABNORMALITIES  
IN KAWASAKI DISEASE
Abstract: I n t r o d u c t i o n: Kawasaki disease is the number one cause of acquired heart disease 
among children in developed countries.
The aim: The aim of the study was a retrospective analysis of the factors that may influence 
the persistence of coronary artery abnormalities in patients with Kawasaki disease. 
M a t e r i a l s  a n d  M e t h o d s: Analyzing the medical records of patients hospitalized in the 
University Children’s Hospital of Krakow in the years 2005–2011 we collected the data of 28 
patients diagnosed with Kawasaki disease. The group was divided into two subgroups, depending 
on the duration of the persistence of changes in the coronary arteries — A (n = 17) for up to 
6 months, B (n = 11) — for more than 6 months. Both groups were analyzed for the presence 
of factors that may influence the course of the disease. 
R e s u l t s: There were more boys in group A (11 boys (65%), 6 girls (35%)), whereas in group B 
the distribution was more uniform (6 boys (55%), 5 girls (45%)). The age of onset in group A was 
37.9 months (SD 30.8), in group B 39.5 months (SD 16.7). 17.6% of patients in group A and 
36.4% in group B were treated with glucocorticoids. 
C o n c l u s i o n s: In the group of patients in which coronary artery abnormalities disappeared 
more quickly, male and slightly older children dominated. The only difference observed between 
the 2 groups related to the frequency of the use of glucocorticoids, they were used more often 
in children, in whom coronary artery abnormalities persisted longer.
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INTRODUCTION
Kawasaki disease is currently the number one cause of acquired coronary artery 
disease in young children in developed countries [1, 2]. 
It is an acute, self-limited, systemic vasculitis of unknown etiology that 
usually occurs in early childhood. In the course of Kawasaki disease the co-
ronary arteries are most often affected. Aneurysms, or ectasia of the coronary 
arteries occur in 15–25% of untreated children with Kawasaki disease and 
may lead to the development of ischemic heart disease, including myocardial 
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infarction and even sudden death. Kawasaki disease is now linked with ear-
ly-onset and accelerated atherosclerosis [3], a leading cause of heart disease in 
adults. Recent studies also suggest that early and aggressive treatment of the 
blood vessel inflammation caused by Kawasaki Disease may reduce the future 
risk of developing accelerated atherosclerosis [4].
Aneurysms most commonly form in the proximal segment of the left ante-
rior descending artery from the left coronary artery and the proximal segment 
of the right coronary artery, less frequently in the left main coronary artery, 
the circumflex coronary artery, and the terminal segment of the right coronary 
artery [5]. The shape and size of aneurysms may change with time.
Aneurysms can increase their size during the first 4–6 weeks after the on-
set of the disease. After reaching their peak size, 50% of aneurysms disappear 
and the vessels return to their normal diameter in the next two years (after the 
onset of the illness), after this period of time, further regression usually does not 
occur [6]. Factors that improve the prognosis in patients who develop coronary 
artery aneurysms are: younger age and localization in the distal segments of 
the coronary arteries.
THE AIM
The aim of the study was a retrospective analysis of the factors that may 
influenced the persistence of coronary artery abnormalities in patients with 
Kawasaki disease. 
MATErIALs And METHods
Based on the retrospective analysis of medical records of patients hospitalized 
at the University Children’s Hospital of Krakow in the years 2005–2011 we 
collected the data of 28 patients who were diagnosed with Kawasaki disease. 
The development and regression of coronary arteries aneurysms was assessed by 
echocardiography. Each patient had a series of echocardiographic assesments 
done with a frequency that corresponded to local standards. Afterwards, the 
results of the subsequent control echocardiograms of each patient that were 
performed during the follow-up period were analyzed and the study group was 
divided into two subgroups. 
The mean follow-up period was 612 days. Each of the patients had an 
average of 4.3 control echocardiographies performed.
The first group — Group A — included patients in whom no coronary 
artery abnormalities had been observed, or such an abnormality had been dia-
gnosed in at least one artery and had completely withdrawn during the 6-month 
observation period. 
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The second study group — Group B — consisted of patients, in whom at 
least one coronary artery aneurysm had persisted for more than 6 months after 
the initial diagnosis. 
According to criteria established by the Japanese Ministry of Health [7] coro-
nary arteries are classified as abnormal if the internal diameter of the lumen is 
>3 mm in children <5 years old or >4 mm in children ≥5 years old; if the internal 
diameter of a segment exceeds at least 1.5 times the size of an adjacent segment 
or if the coronary lumen is irregular. For the purpose of this study, patients with 
coronary artery abnormalities were defined as having coronary artery aneurysms 
confirmed by echocardiography, based on measurements of the internal diameter 
of the lumen according to the Japanese Ministry of Health criteria. Irregularity 
of the coronary artery lumens was not assessed.
Echocardiographic analysis was performed using a echocardiographic system 
Sonos 5500, Philips Medical Systems, Amsterdam, the Netherlands, with a Philips 
S8 Cardiac Probe. The echocardiographic assessment was standardized and per-
formed only by two operators in order to avoid significant interobserver variability.
Afterwards the two groups were analyzed in respect to the prevalence of fac-
tors that may influence the course of the disease, such as demographic data, 
laboratory results and the administered treatment.
RESULTS
The study included 28 patients, group A consisted of 17 patients and group 
B of 11 patients. The demographic and clinical characteristics of both groups are 
presented in Table 1 and the laboratory test results in Table 2. The distribution 
of coronary artery aneurysms and the mean time period of regression for group 
A is presented in Table 3, and for group B in Table 4.
Evaluating the variability of infectious parameters over time, we can see 
that there was a considerable, although not statistically significant, difference in 
CRP levels between the two groups. In the first days of the disease, higher CRP 
values  were observed in group B (Figure 1).
Analyzing the course of the fever, it was observed that the variability was 
very similar in both groups, in addition absolute body temperatures also co-
incided (Figure 2).
Intravenous immune globulin therapy was administered to all patients 
enrolled in group A and to 91% of patients in group B. The total dose of im-
mune globulins administered in group A was on average 30.4 ± 14.3 g, whi-
le in group B, 30.1 ± 11.5 g. In Group A intravenous immune globulins were 
administered in a single infusion to 3 patients, in 2 infusions to 10 patients, and 
in 3 to 4 patients. The respective values  for group B were 2 patients, 6 pa-
tients and 2 patients, as visualized in Figure 3. 
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T a b l e  1
Demographic and clinical characteristics of the study groups.
Group A Group B p value
Number of patients 17 (61%) 11 (39%)
Male gender 11 6 0,592
Age at the onset of KD [months] 38,9 (SD 6,3) 37,9 (SD 7,8) 0,921
Weight at the onset of KD [kg] 15,6 (SD 6,7) 14,7 (SD 3,6) 0,641
Duration of fever until administration  
of treatment [days]
 9,8 (SD 2,3)  8,1 (SD 3,2) 0,441
1 student’s t Test
2 Fisher’s exact test
  Kd — Kawasaki disease
T a b l e  2
Laboratory test results in study groups.
Group A Group B p value
Maximum ESR [mm after 1 hour]
87,4 
SD 41,4
91,6 
SD 29,1
0,661
Highest CrP [mg/l]
140,7
SD 65,1
169,2
SD 113,0
0,351
Highest value for Leukocytosis [cell/ul]
20 500
SD 5 600
17 400
SD 6 500
0,931
Highest value for Platelet count [cell/ul]
715 000 
SD 160 000
793 000 
SD 296 000
0,231
1 student’s t Test
T a b l e  3
Coronary aneurysms distribution in group A.
Group A, n=17 LMCA LAD Cx RCA
No of patients with aneurysm 8 4 1 5
No of patients without aneurysm 5
Mean time to complete regression (days, SD)
22,6
SD 14,1
33,0
SD 25,6
9
(1 patient)
18,0
SD 17,8
17
The first dose of immune globulins was administered on average in both 
groups on the 8.5 day of illness (SD 3.8 day). Glucocorticoids (GCs) were 
included in the therapy of 17.6% of patients in group A and in 36.4% of pa-
tients in group B. 
Glucocorticoids were included in the therapy of patients in the following 
clinical situations: presence of joint involvement, the desire to minimize the 
risk of an allergic reaction to immune globulins, visibility of pericardial ef-
fusion or myocardial contractility disorders in echocardiographic studies, and 
finally resistant forms of Kawasaki disease.
All patients were treated with high-dose aspirin (80–100 mg/kg/day) which 
was introduced in both groups on average on the 9 ± 4.5 day of illness.
T a b l e  4
Coronary aneurysms distribution in group B.
Group B, n=11 LMCA LAD Cx RCA
No of patients with aneurysm 10 7 5 8
No of patients without regression of aneurysm   6 2 0 1
Mean time to complete regression (days, SD)
494,5 
SD 262,7
191,0 
SD 315,7
191,6 
SD 316,4
193,0 
SD 147,3
 
0
50
100
150
200
250
300
0 5 10 15 20 25 30 35
Day of ilness
C
R
P 
[m
g/
l]
Group A Group B IvIg administration
Fig. 1. Variability of CRP depending of the day of illness.
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DISCUSSION
Several years have passed since the first clinical description of a patient with 
Kawasaki disease (Kawasaki Tomisaku, 1962) and linkage of the disease with 
abnormalities in the coronary arteries (Noboru Tanaka, 1965) [8]. Since that 
time, there is no doubt that the most serious complications in the course 
of the systemic vasculitis, which is Kawasaki disease are associated with the 
development of abnormalities in the coronary circulation, which can then lead 
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Fig. 2. Variability of the body temperature depending of the day of illness.
Fig. 3. Number of immune globulin infusions in both groups.
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to myocardial ischemia, myocardial infarction, arrhythmia or even sudden death. 
Therefore researchers have often tried to select a group of patients diagnosed 
with Kawasaki disease, that are particularly at risk of developing complications 
in the form of pathological changes in the coronary arteries and their subsequent 
consequences. 
Based on numerous publications we know that boys are affected more often 
by Kawasaki disease than girls (60 vs 40%) [9–13], similar findings were also noted 
in the analyzed population. Elevated inflammatory markers such as CRP [14] or 
ESR [15], predispose to the development of aneurysms and increase the risk of 
complications which was also observed in our study group. An additional adverse 
prognostic factor is an elevated platelet count in the initial phases of the disease 
[16], we also found this to be true. 
Other factors affecting the prognosis are atypical age of onset of Kawasaki 
disease (less than 1 year of age34 or over 6 years of age [17]), hypoalbumi-
nemia [18], low hematocrite [19] or hyponatremia [20]. Most probably due to 
the limited size of the study group, we failed to observe such patterns in the 
above analyzed population.
Analysing the factors that contributed to a poorer prognosis in patients with 
Kawasaki disease based on the analysis of our data, we found that if a correlation 
between age and body weight was taken into account — it seemed that patients 
who were slightly younger and with a lower body weight had worse prognosis. 
Patients with a poorer prognosis also had a slightly lower leukocytosis, coupled 
with increased inflammatory markers such as ESR or CRP. It should be noted, 
that the authors did not find any confirmation of these observations in the latest 
publications.
The majority of patients received intravenous immune globulins at a dose 
of 2 gm/kg of in two consecutive infusions. Ever since there have been reports 
of improved disease outcome after immune globulin administration in a single 
infusion, the treatment strategy at our hospital has changed and patients 
have started receiving one instead of two. There was a small group of patients 
who received 3 doses of immune globulins. These patients had been referred 
from a district hospital and most of them had received a very low dose of immune 
globulins therefore the decision was made to launch a full treatment regimen 
after the admission of these patient to the University Children’s Hospital.
Results of the latest published trial [21] suggest that the addition of pred-
nisolone to the standard regimen of intravenous immune globulins and aspirin 
improves coronary artery outcomes in patients with severe Kawasaki Disease. In 
patients from this study 2 types of steroids were used; hydrocortisone and pred-
nisolone, furthermore they were not part of the standard treatment but added 
to immune globulins and aspirin in certain clinical situations such as presence 
of joint involvement, minimizing the risk of an allergic reaction to immune 
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globulins, visibility of pericardial effusion or myocardial contractility disorders 
in echocardiographic studies, and finally resistant forms of Kawasaki disease.
Based on the analysis of data concerning patients diagnosed with Kawasaki 
disease, we can conclude that in the group of patients in whom abnormalities 
in the coronary arteries disappeared more quickly, male and slightly older 
children with a higher body weight dominated. Lower levels of inflammatory 
markers such as ESR, CRP, lower platelet counts but a higher leukocytosis 
were also observed. Analyzing the treatment regimen administered to both 
groups of patients, we can conclude that it was quite similar. The only dif-
ference observed between the 2 groups related to the frequency of the use 
of glucocorticoids, they were used more often in children, in whom coronary 
artery abnormalities persisted longer than 6 months. It must be taken into 
account though that the patients from that group had higher inflammatory 
markers such as CRP, ESR, a higher platelet count and a slightly earlier 
time of introduction of immune globulins so that the increased incidence of 
complications could not necessarily have resulted from the use of the steroids 
but a more severe disease course. 
The aim of this paper was a retrospective analysis of pre-defined groups 
of patients and should not be used as a basis for defining risk factors that 
influence the prognosis of patients diagnosed with Kawasaki disease in the 
future. Notwithstanding we hope that our results could be taken into account in 
planning further studies aimed at a detailed analysis of the above mentioned 
factors in the future.
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